Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK,

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

The Diabetic Retinopathy Clinical Research Network
CBER Isolagen Therapy (IT) BLA FDA Clinical Review Agnes Lim, MD Yao-Yao Zhu, MD, PhD DCEPT/OCTGT/CBER, FDA October 9, 2009 Advisory Committee Meeting.
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The ERICA Trial Peter H. Stone, MD, FACC, Nikolay A. Gratsiansky, MD, Alexey Blokhin, MD, I-Zu Huang, MD, Lixin Meng, MS, MPH, for the ERICA Investigators.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Phase 2 of new ARVs BMS (maturation inhibitor)
Dejun Tang, Novartis Pharma, China PSI Webinar July 16, 2015 Challenges and Opportunities on Multi-regional Clinical Trials Including Asian Countries.
Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Yesterday, today, and tomorrow
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
A Double-Blind, Randomized, Placebo-Controlled Study of Calcium Glycerophosphate Dietary Supplement in Patients with Overactive Bladder Michael J. Kennelly,
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.
Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.
ACAMPROSATE Efficacy Results from Three Pivotal Efficacy Trials Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and.
Raymond F. Anton, MD for The COMBINE Study Research Group
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Over active bladder drug treatment Mark Weatherall University of Otago Wellington.
ECONOMIC EVALUATION OF THE USE OF OXYBUTYNIN, TOLTERODINE AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER February 6, 2009.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Update On OAB Joon Chul Kim The Catholic University of Korea.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
International Neurourology Journal 2015;19: Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome Chun-Hou.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Robert A. Terkeltaub, Daniel E. Furst, Katherine Bennett, Karin A. Kook, R. S. Crockett, and Matthew W. Davis ARTHRITIS & RHEUMATISM Vol. 62, No. 4, April.
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Long term effectiveness of perampanel: the Leeds experience Jo Geldard, Melissa Maguire, Elizabeth Wright, Peter Goulding Leeds General Infirmary, Leeds.
Alcohol, Other Drugs, and Health: Current Evidence
Efficacy and Safety of Dabigatran vs
Neal B, et al. Diabetes Care 2015;38:403–411
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Volume 54, Issue 4, Pages (October 2008)
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Difference between the groups
Presentation transcript:

Revolution in Asian drug development: A Korea and Japan experience Henk de Koning Gans, MD VP, Process Management Global Development Japan Pharmacia KK, Japan

Agenda Background Regulatory considerations Trial design and results Implementation in Korea and Japan Conclusions

ICH in US-EU-Japan Japan is a part of ICH Korea is implementing ICH standards Pan-European studies are universally accepted Pan-Asian studies including Japan are a novelty in regulatory submissions

The drug: Tolterodine Developed specifically for overactive bladder Selective for bladder over salivary glands Approved for the treatment of overactive bladder or unstable bladder in 57 countries, with more than 6 million people treated worldwide Nilvebrant L et al. Life Sci. 1997;60:

The disease: Overactive Bladder Overactive bladder (OAB) is a symptom syndrome characterized by: Urgency, with or without urge incontinence, usually with frequency and nocturia Abrams et al. Neurourology and Urodynamics. 2002; 21:

Messelink EJ. BJU Int. 1999;83(suppl 2): Overview of Tolterodine Global Clinical Program Largest clinical development program ever conducted for an overactive bladder (OAB) compound 32 registration studies conducted (17 phase I; 4 phase II; 11 phase III) in 16 countries More than 4,000 patients treated; more than 3,000 received tolterodine in controlled studies

Tolterodine Extended Release (ER) Provides improved efficacy and tolerability Provides constant plasma over 24 hours Significantly greater reduction in incontinence episodes than with tolterodine immediate release (IR) Lower incidence of dry mouth than tolterodine IR Convenience of once-daily dosing

Regulatory Considerations Traditional development: - EU/US file + Japan development program - Korean registration study for NCEs

Japanese Trial Environment after 1998 Slow implementation of ICH GCP infrastructure Slow patient recruitment in all therapeutic areas Other key hurdles – comparator drug - difficulty to obtain informed consent - patients reluctant to participate in placebo controlled trials

Korean Trial Environment GCP legislation since 1995 ICH standard implementation since 2000 Institutions designated by KFDA for clinical research –Phase I: 17 centers, Phase II: 49 centers, Phase III: 72 centers with regular IRB review and training (Korean Association of IRB) Faster patient enrollment than Japan Reasonable cost Hurdles – relatively long clinical trial authorization (5-6 ms) –low public awareness of the need for clinical trials

Korean Trial Environment New regulations on Evaluation of Safety and Efficacy of Drugs Major implications & benefits  Possible to join global development program  Waiver for a local registration trial  Accelerated product approval in Korea

ICH in US-EU-Japan Japan is a part of ICH Korea is implementing ICH standards Pan-European studies are universally accepted Pan-Asian studies including Japan are a novelty in regulatory submissions

Regulatory Considerations A combined Korean-Japanese Phase III registration study was proposed Agreement needed with the health authorities in both Korea and Japan (i.e. KFDA and KIKO) – Primary study endpoint agreed – Korean and Japanese populations comparable – ICH GCP compliance

Clinical Efficacy and Safety of Tolterodine ER in Korean and Japanese Patients With OAB A phase III, 12-week, randomized, double- blind, double dummy, placebo- and active (oxybutynin)-controlled, multicenter study

Study Design Design similar to previous Phase III study in Europe, US, Australia, and New Zealand 1 Double-blind, double dummy, randomized, parallel design Study periods: – 1- to 2-week wash-out/run-in period – 12-week treatment period – 1- to 2-week post-treatment follow-up Treatments: – tolterodine ER 4 mg qd (approved dose in the US and EU) – oxybutynin 3 mg tid (approved dose in Korea and Japan) – placebo 1. Van Kerrebroeck P et al. Urology. 2001;57:

Study Design Tolterodine ER 4 mg QD n = 240 Placebo n = 122 Oxybutynin IR 3 mg TID n = 246 N = week double-blind treatment 1-2 week follow- up No statistically significant difference between groups in demographics or baseline disease characteristics. 1–2 week washout/run-in

Summary of patient distribution CountryNumber of Centers Number of patients PlaceboTolterodine ER 4 mg qd Oxybutynin 3 mg t.i.d.Total Korea Japan Total Data on file, Pharmacia Corporation.

Demographics and Baseline Characteristics Placebo (n = 122) Tolterodine ER 4 mg q.d. (n = 240) Oxybutynin 3 mg t.i.d. (n = 246) Sex (%) Male Female Age (years) Mean Range Micturition Chart Variables (%)  8 micturitions/24 hrs  5 incontinence episodes/wk  200 mL mean volume voided per micturition Data on file, Pharmacia Corporation.

Efficacy Variables Primary: Median % change in number of incontinence episodes per week Secondary: Number of micturitions per 24 hours Volume voided per micturition Number of pads used per 24 hours Patient ’ s perception of bladder condition, treatment benefit, and urgency

Decrease in Urge Incontinence Episodes * ** *P<0.005 versus placebo **P<0.05 versus placebo Placebo (n=122) Tolterodine ER (n = 239) Oxybutynin (n = 244) Data on file, Pharmacia Corporation.

Decrease in Micturitions Per 24h Placebo (n=122) Tolterodine ER (n = 239) Oxybutynin (n = 244) * ** *P<0.001 versus placebo **P<0.05 versus placebo Data on file, Pharmacia Corporation.

Change in Mean Volume Voided Per Micturition Placebo (n=122) Tolterodine ER (n = 239) Oxybutynin (n = 244) *P<0.005 versus placebo **P<0.001 versus placebo * ** Data on file, Pharmacia Corporation.

Incidence and Severity of Dry Mouth Data on file, Pharmacia Corporation. % of Patients

Other Adverse Events Data on file, Pharmacia Corporation. % of Patients

Premature Withdrawals Total Withdrawals Withdrawals Due to AEs Data on file, Pharmacia Corporation.

Decrease in Urge Incontinence Episode Comparison of EU/US and K/J trials * ** *P<0.005 versus placebo **P<0.05 versus placebo Placebo (n=122) Tolterodine ER (n = 239) Oxybutynin (n = 244) Data on file, Pharmacia Corporation. Van Kerrebroeck et al. Urology. 2001;57: *P < 0.01 vs placebo † P < 0.05 vs IR Median % Reduction from Baseline –70 –80 –60 –50 –30 –20 –10 0 Tolterodine ER Tolterodine IR Placebo –40 * †* † * –71% –60% –33% Median % change From Baseline

Conclusions I First ever Korean-Japanese study for registration in Asian countries Tolterodine ER is equally effective to, and better tolerated than, oxybutynin IR in Korean and Japanese patients with OAB Total withdrawals and withdrawals due to AEs were 2- and 3-fold higher, respectively, with oxybutynin IR than with tolterodine ER Similar response between Korean and Japanese patient populations Results are also consistent with those of Western studies of these agents

Enrollment chart in Korea and Japan 2 nd Adv. 8 April 1 st Adv. 11 March 3 rd Adv. 12 May Adv. March

Enrollment chart in Japan rd Adv 12 May 2 nd Adv 8 April 1 st Adv. 11 March

Clinical trials are speeding up – experience in Japan Migraine Hypertension Anti-fungal Anti-fungal

Key success factors for this Korea-Japan trial 1.Trial center selection and preparation 2.Investigator training 3.Newspaper ads and call / referral center 4.Global data management 5.Global team 6.Think the unthinkable!

Conclusion II 1.High quality data obtained in Korea and Japan 2.Study results confirm global consistency of drug profile 3.Study completed in record time (5 months FPI-LPI) New approaches used successfully: 1.Trial center selection 2.Investigator training 3.Newspaper ads and call / referral center